VentureSouth, one of the top 10 angel investment groups in the United States with nearly 350 members, announces another record-breaking level of investing during the first half of 2019.
To the end of June, VentureSouth members and fund investors invested $4.8 million into 17 companies. This was 24% more than the $3.9 million invested during the same period in 2018.
New companies receiving initial investments this year include Zylo Therapeutics, a nano-technology based drug delivery system; OffSite, a platform for better offsite advertising; and Aperiomics, the creators of a single test to diagnose all infectious diseases.
Multiple existing VentureSouth portfolio companies also received additional funding, including KIYATEC, a drug optimization platform; Emergo Therapeutics, a biopharma company developing a treatment to control the body’s immune response; and Spiffy, a platform for vehicle maintenance and a leader in “vehicle 2.0.”
The group also saw another positive exit this year, when Columbia-based Cirtemo was acquired by ThorLabs. VentureSouth was also recognized by the Angel Capital Association as one of the top 10 angel groups in North America.
Managing Director Paul Clark commented, “2019 has been another busy and rewarding year at VentureSouth so far. We continue to attract investors from across the Carolinas eager to join our mission to Make Money, Have Fun, and Do Good. We continue funding some of the leading companies in the southeast. And we continue returning capital to our members. The breadth of investment activity, the collective brainpower of nearly 350 members, and the established and professional team leading the activity set us apart from other providers of capital for startups, and we look forward to continuing to redefine angel investment in the region.”
To learn more about VentureSouth’s Portfolio, visit www.venturesouth.vc/ourportfolio.